{"id":"tobramycin","brandName":"Tobi","genericName":"tobramycin","companyId":"novartis","companyName":"Novartis","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)"},"administration":{"route":"Intravenous"},"safety":{"boxedWarnings":["WARNINGS Patients treated with Tobramycin Injection and other aminoglycosides should be under close clinical observation, because these drugs have an inherent potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested as both auditory and vestibular ototoxicity, can occur. The auditory changes are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve impairment and nephrotoxicity may develop, primarily in patients having pre-existing renal damage and in those with normal renal function to whom aminoglycosides are administered for longer periods or in higher doses than those recommended. Other manifestations of neurotoxicity may include numbness, skin tingling, muscle twitching, and convulsions. The risk of aminoglycoside-induced hearing loss increases with the degree of exposure to either high peak or high trough serum concentrations. Patients who develop cochlear damage may not have symptoms during therapy to warn them of eighth-nerve toxicity, and partial or total irreversible bilateral deafness may continue to develop after the drug has been discontinued. Rarely, nephrotoxicity may not become apparent until the first few days after cessation of therapy. Aminoglycoside-induced nephrotoxicity usually is reversible. Renal and eighth-nerve function should be closely monitored in patients with known or suspected renal impairment and also in those whose renal function is initially normal but who develop signs of renal dysfunction during therapy. Peak and trough serum concentrations of aminoglycosides should be monitored periodically during therapy to assure adequate levels and to avoid potentially toxic levels. Prolonged serum concentrations above 12 mcg/mL should be avoided. Rising trough levels (above 2 mcg/mL) may indicate tissue accumulation. Such accumulation, excessive peak concentrations, advanced age, and cumulative dose may contribute to ototoxicity and nephrotoxicity (see PRECAUTIONS ). Urine should be examined for decreased specific gravity and increased excretion of protein, cells, and casts. Blood urea nitrogen, serum creatinine, and creatinine clearance should be measured periodically. When feasible, it is recommended that serial audiograms be obtained in patients old enough to be tested, particularly high-risk patients. Evidence of impairment of renal, vestibular, or auditory function requires discontinuation of the drug or dosage adjustment. Tobramycin should be used with caution in premature and neonatal infants because of their renal immaturity and the resulting prolongation of serum half-life of the drug. Concurrent and sequential use of other neurotoxic and/or nephrotoxic antibiotics, particularly other aminoglycosides (e.g., amikacin, streptomycin, neomycin, kanamycin, gentamicin, and paromomycin), cephaloridine, viomycin, polymyxin B, colistin, cisplatin, and vancomycin, should be avoided. Other factors that may increase patient risk are advanced age and dehydration. Aminoglycosides should not be given concurrently with potent diuretics, such as ethacrynic acid and furosemide. Some diuretics themselves cause ototoxicity, and intravenously administered diuretics enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. Aminoglycosides can cause fetal harm when administered to a pregnant woman (see PRECAUTIONS )."],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"2161 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"1740 reports"},{"date":"","signal":"INFECTIVE PULMONARY EXACERBATION OF CYSTIC FIBROSIS","source":"FDA FAERS","actionTaken":"1575 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"1565 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1506 reports"},{"date":"","signal":"COUGH","source":"FDA FAERS","actionTaken":"1340 reports"},{"date":"","signal":"CYSTIC FIBROSIS","source":"FDA FAERS","actionTaken":"1279 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1051 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"1043 reports"},{"date":"","signal":"HOSPITALISATION","source":"FDA FAERS","actionTaken":"1027 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Hearing loss","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Vertigo","drugRate":"","severity":"common","organSystem":""},{"effect":"Tinnitus","drugRate":"","severity":"common","organSystem":""},{"effect":"Roaring in the ears","drugRate":"","severity":"common","organSystem":""},{"effect":"Rising BUN","drugRate":"","severity":"common","organSystem":""},{"effect":"Rising serum creatinine","drugRate":"","severity":"common","organSystem":""},{"effect":"Oliguria","drugRate":"","severity":"common","organSystem":""},{"effect":"Cylindruria","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased proteinuria","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Itching","drugRate":"","severity":"common","organSystem":""},{"effect":"Urticaria","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"","severity":"common","organSystem":""},{"effect":"Lethargy","drugRate":"","severity":"common","organSystem":""},{"effect":"Pain at injection site","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Bacterial infection of eye","Dehydration","Diabetes mellitus","Disorder of the 8th Cranial Nerve","Eye infection","Fungal infection of eye","Glaucoma","Herpes simplex dendritic keratitis","Herpes simplex keratitis","Herpes zoster ophthalmicus","Hypocalcemia","Hypomagnesemia","Infant Botulism","Kidney disease","Krukenberg spindle","Myasthenia gravis","Ocular hypertension","Open-angle glaucoma","Parkinsonism","Pregnancy, function","Pseudomembranous enterocolitis","Severe myopia","Tinnitus","Tobramycin Toxicity","Tuberculosis of eye","Vaccinia keratitis","Vertigo","Viral eye infection"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Ototoxicity","drugRate":"","severity":"serious"},{"effect":"Nephrotoxicity","drugRate":"","severity":"serious"},{"effect":"Granulocytopenia","drugRate":"","severity":"serious"},{"effect":"Thrombocytopenia","drugRate":"","severity":"serious"},{"effect":"Anemia","drugRate":"","severity":"serious"},{"effect":"Exfoliative dermatitis","drugRate":"","severity":"serious"},{"effect":"Mental confusion","drugRate":"","severity":"serious"},{"effect":"Disorientation","drugRate":"","severity":"serious"},{"effect":"Leukopenia","drugRate":"","severity":"serious"},{"effect":"Leukocytosis","drugRate":"","severity":"serious"}]},"trials":["NCT00004829","NCT02712983","NCT01102244","NCT01456780","NCT01953367","NCT02178540","NCT03341741","NCT02248922","NCT01270347","NCT00774072","NCT02489955","NCT04624035","NCT03875963","NCT00257790","NCT05849090","NCT02440828","NCT04964947","NCT00035425","NCT01069705","NCT02038803","NCT03822312","NCT07332936","NCT00783757","NCT00050401","NCT01559753","NCT04122300","NCT01082367","NCT04571788","NCT01400750","NCT04342507","NCT05429671","NCT01155999","NCT03739528","NCT03308253","NCT04850313","NCT02528123","NCT04213313","NCT00781300","NCT01116089","NCT00357773","NCT01230593","NCT00885365","NCT00388505","NCT03673956","NCT01641822","NCT03715322","NCT00006280","NCT04872400","NCT04297631","NCT02734459"],"indications":{"approved":[{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Anterior uveitis","diseaseId":"anterior-uveitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial conjunctivitis","diseaseId":"bacterial-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial infection due to Klebsiella pneumoniae","diseaseId":"bacterial-infection-due-to-klebsiella-pneumoniae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial infection due to Serratia","diseaseId":"bacterial-infection-due-to-serratia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial meningitis","diseaseId":"bacterial-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial peritonitis","diseaseId":"bacterial-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial septicemia","diseaseId":"bacterial-septicemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial urinary infection","diseaseId":"bacterial-urinary-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Blepharoconjunctivitis","diseaseId":"blepharoconjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Citrobacter Complicated UTI","diseaseId":"citrobacter-complicated-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Proteus UTI","diseaseId":"complicated-proteus-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated UTI with Pseudomonas Aeruginosa","diseaseId":"complicated-uti-with-pseudomonas-aeruginosa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Urinary Tract Infections","diseaseId":"complicated-urinary-tract-infections","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Corneal abrasion","diseaseId":"corneal-abrasion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Dacryocystitis","diseaseId":"dacryocystitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Osteomyelitis","diseaseId":"e.-coli-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Peritonitis","diseaseId":"e.-coli-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Enterobacter Osteomyelitis","diseaseId":"enterobacter-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Enterobacter Pneumonia","diseaseId":"enterobacter-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Escherichia coli urinary tract infection","diseaseId":"escherichia-coli-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gram-Negative Aerobic Bacillary Pneumonia","diseaseId":"gram-negative-aerobic-bacillary-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Herpes zoster keratitis","diseaseId":"herpes-zoster-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Enterobacteriaceae","diseaseId":"infection-due-to-enterobacteriaceae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Escherichia coli","diseaseId":"infection-due-to-escherichia-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection of bone","diseaseId":"infection-of-bone","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infective blepharitis","diseaseId":"infective-blepharitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Keratoconjunctivitis","diseaseId":"keratoconjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella Pneumoniae Osteomyelitis","diseaseId":"klebsiella-pneumoniae-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella Pneumoniae Peritonitis","diseaseId":"klebsiella-pneumoniae-peritonitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Meibomianitis","diseaseId":"meibomianitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Neonatal meningitis","diseaseId":"neonatal-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nosocomial pneumonia","diseaseId":"nosocomial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Osteomyelitis due to Staphylococcus aureus","diseaseId":"osteomyelitis-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Perforation of cornea","diseaseId":"perforation-of-cornea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Escherichia coli","diseaseId":"pneumonia-due-to-escherichia-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Pseudomonas","diseaseId":"pneumonia-due-to-pseudomonas","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Proteus Mirabilis Osteomyelitis","diseaseId":"proteus-mirabilis-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Providencia Complicated UTI","diseaseId":"providencia-complicated-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pseudomonas Aeruginosa Osteomyelitis","diseaseId":"pseudomonas-aeruginosa-osteomyelitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Punctate keratitis","diseaseId":"punctate-keratitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rhinoscleroma","diseaseId":"rhinoscleroma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rosacea","diseaseId":"rosacea","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis due to Pseudomonas","diseaseId":"sepsis-due-to-pseudomonas","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sepsis of the newborn","diseaseId":"sepsis-of-the-newborn","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Septicemia due to Escherichia coli","diseaseId":"septicemia-due-to-escherichia-coli","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Serratia Complicated UTI","diseaseId":"serratia-complicated-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin and Skin Structure Proteus Infection","diseaseId":"skin-and-skin-structure-proteus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin and Skin Structure Pseudomonas Aeruginosa Infection","diseaseId":"skin-and-skin-structure-pseudomonas-aeruginosa-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal pneumonia","diseaseId":"staphylococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Aureus Complicated UTI","diseaseId":"staphylococcus-aureus-complicated-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synergy for Bacterial Meningitis","diseaseId":"synergy-for-bacterial-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synergy for Neonatal Meningitis","diseaseId":"synergy-for-neonatal-meningitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa","diseaseId":"synergy-for-nosocomial-pneumonia-due-to-pseudomonas-aeruginosa","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synergy for P. Aeruginosa Infection in Cystic Fibrosis","diseaseId":"synergy-for-p.-aeruginosa-infection-in-cystic-fibrosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Synergy for Staphylococcal Infections","diseaseId":"synergy-for-staphylococcal-infections","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urinary tract infection caused by Klebsiella","diseaseId":"urinary-tract-infection-caused-by-klebsiella","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Uveitis","diseaseId":"uveitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Formulation","number":"8869794","applicant":"VIATRIS SPECIALTY LLC","territory":"US","tradeName":"TOBI PODHALER","expiryDate":"2028-09-12"},{"type":"Formulation","number":"10207066","applicant":"VIATRIS SPECIALTY LLC","territory":"US","tradeName":"TOBI PODHALER","expiryDate":"2030-11-04"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT00004829","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","isPivotal":true,"enrollment":200,"indication":"Cystic Fibrosis, Bacterial Infection","completionDate":"1998-05"},{"nctId":"NCT02712983","phase":"Phase 2","title":"A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic F","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":107,"indication":"Non-cystic Fibrosis Bronchiectasis","completionDate":"2019-03-20"},{"nctId":"NCT01102244","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Alcon Research","isPivotal":true,"enrollment":122,"indication":"Blepharitis","completionDate":""},{"nctId":"NCT01456780","phase":"Phase 4","title":"Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blephari","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","isPivotal":false,"enrollment":60,"indication":"Meibomian Gland Dysfunction, Posterior Blepharitis","completionDate":"2017-06"},{"nctId":"NCT01953367","phase":"Phase 1","title":"Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects","status":"COMPLETED","sponsor":"Pari Pharma GmbH","isPivotal":false,"enrollment":72,"indication":"Cystic Fibrosis","completionDate":"2013-11"},{"nctId":"NCT02178540","phase":"Phase 4","title":"A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using ","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":45,"indication":"Cystic Fibrosis","completionDate":"2015-02"},{"nctId":"NCT03341741","phase":"Phase 3","title":"Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients","status":"COMPLETED","sponsor":"University Hospital Tuebingen","isPivotal":true,"enrollment":26,"indication":"Cystic Fibrosis With Pulmonary Manifestations","completionDate":"2016-11-25"},{"nctId":"NCT02248922","phase":"Phase 4","title":"An 8 Week Open-label Interventional Multicenter Study to Evaluate the Lung Clearance Index as Endpoint for Clinical Trials in Cystic Fibrosis Patients ≥ 6 Years of Age, Chronically Infected With Pseud","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":17,"indication":"Chronic Lung Infection With Pseudomonas Aeruginosa in Cystic Fibrosis","completionDate":"2017-04-10"},{"nctId":"NCT01270347","phase":"Phase 3","title":"Phase 3, Open-label, Randomized Trial to Evaluate the Safety and Efficacy of MP-376 Inhalation Solution (Aeroquin) vs. Tobramycin Inhalation Solution (TIS) in Stable CF Patients","status":"COMPLETED","sponsor":"Amgen","isPivotal":true,"enrollment":282,"indication":"Cystic Fibrosis","completionDate":"2013-06"},{"nctId":"NCT00774072","phase":"Phase 2","title":"Nasal Inhalation of Tobramycin by the Pari Sinus Nebulizer in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization in the Upper Airways","status":"COMPLETED","sponsor":"University of Jena","isPivotal":false,"enrollment":9,"indication":"Cystic Fibrosis, Pseudomonas Aeruginosa","completionDate":"2010-11"},{"nctId":"NCT02489955","phase":"NA","title":"Prospective Randomised Trial of 'Area Under the Curve' (AUC) Dosing Strategy for Intravenous Tobramycin Versus Standard Trough Dosing for Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis","status":"UNKNOWN","sponsor":"The Leeds Teaching Hospitals NHS Trust","isPivotal":false,"enrollment":0,"indication":"Cystic Fibrosis","completionDate":""},{"nctId":"NCT04624035","phase":"NA","title":"Comparison Between Implantable Phakic Intraocular Lens and Implantable Collamer Lens in Treatment of Myopia in Adults","status":"UNKNOWN","sponsor":"Assiut University","isPivotal":false,"enrollment":60,"indication":"Myopia","completionDate":"2021-10"},{"nctId":"NCT03875963","phase":"NA","title":"Performance of Antibiotic Impregnated Calcium Sulfate: A Prospective Randomized Controlled Trial","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","isPivotal":false,"enrollment":100,"indication":"Fracture Non Union, Infection","completionDate":"2022-11-23"},{"nctId":"NCT00257790","phase":"Phase 4","title":"Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber","status":"COMPLETED","sponsor":"Oslo University Hospital","isPivotal":false,"enrollment":210,"indication":"Neutropenia, Fever","completionDate":"2005-03"},{"nctId":"NCT05849090","phase":"EARLY/Phase 1","title":"Pilot for Vancomycin and Tobramycin Powder Use in Acute Open Fractures in the Emergency Department","status":"COMPLETED","sponsor":"University of Utah","isPivotal":false,"enrollment":10,"indication":"Infections","completionDate":"2024-12-12"},{"nctId":"NCT02440828","phase":"Phase 4","title":"Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment","status":"COMPLETED","sponsor":"Erasmus Medical Center","isPivotal":false,"enrollment":80,"indication":"Ventilator Associated Pneumonia (VAP)","completionDate":"2020-07-01"},{"nctId":"NCT04964947","phase":"Phase 3","title":"Does Prophylactic Local Tobramycin Injection Lower Open Fracture Infection Rates?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":true,"enrollment":600,"indication":"Wound Infection, Fractures, Open","completionDate":"2026-07"},{"nctId":"NCT00035425","phase":"Phase 3","title":"A Randomized, Double-Blind Trial Comparing Linezolid To Vancomycin In The Empiric Treatment Of Febrile Neutropenic Oncology Patients With Suspected Gram-Positive Infections","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":120,"indication":"Febrile Neutropenia","completionDate":"2002-11"},{"nctId":"NCT01069705","phase":"Phase 3","title":"A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder After Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Patients Who Success","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":49,"indication":"Pulmonary Infections, Pseudomonas Aeruginosa","completionDate":"2012-03-19"},{"nctId":"NCT02038803","phase":"N/A","title":"Patient Preferences and Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution (PETIS)","status":"TERMINATED","sponsor":"Rush University Medical Center","isPivotal":false,"enrollment":5,"indication":"Cystic Fibrosis","completionDate":"2014-05-07"},{"nctId":"NCT03822312","phase":"NA","title":"A Pilot Study of Digital Breast Tomosynthesis Guided Near-infrared Tomographic Optical Breast Imaging (DBT-TOBI) in Monitoring Response of Breast Cancer to Neoadjuvant Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":30,"indication":"Breast Cancer","completionDate":"2026-12-31"},{"nctId":"NCT07332936","phase":"NA","title":"Effect of Calcium Hydroxide vs. Tobradex Intracanal Medicament on Postoperative Endodontic Pain: A Prospective Trial","status":"COMPLETED","sponsor":"Umm Al-Qura University","isPivotal":false,"enrollment":43,"indication":"Symptomatic Irreversible Pulpitis, Postoperative Endodontic Pain Following Emergency Root Canal Treatment","completionDate":"2024-06-30"},{"nctId":"NCT00783757","phase":"NA","title":"Functional Metabolic Near-infrared Tomographic Optical Breast Imaging (TOBI) to Monitor Response to Neoadjuvant Therapy in Breast Cancer","status":"COMPLETED","sponsor":"Steven Isakoff, MD, PhD","isPivotal":false,"enrollment":30,"indication":"Breast Cancer","completionDate":"2017-06"},{"nctId":"NCT00050401","phase":"Phase 3","title":"Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":500,"indication":"Pneumonia","completionDate":"2004-09"},{"nctId":"NCT01559753","phase":"Phase 4","title":"Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","isPivotal":false,"enrollment":225,"indication":"Pneumonia Ventilator Associated","completionDate":"2002-11"},{"nctId":"NCT04122300","phase":"Phase 3","title":"Euphrasia Eye Drops in Preterm Infants With First Signs of Congestion of Nasolacrimal Duct - a Randomized Double-blind Controlled Trial","status":"COMPLETED","sponsor":"University of Bern","isPivotal":true,"enrollment":84,"indication":"Congenita Nasolacrimal Duct Obstruction, Preterm Neonates","completionDate":"2016-12-16"},{"nctId":"NCT01082367","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo-Controlled, Crossover Multi-Center Study to Assess the Efficacy and Safety of Inhaled Tobramycin Nebuliser Solution (TOBI®) for the Treatment of Early Infections of","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":50,"indication":"Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients","completionDate":"2015-06"},{"nctId":"NCT04571788","phase":"N/A","title":"Treating Rhegmatogenous Retinal Detachment by Foldable Capsular Buckle (FCB): a Randomized, Controlled, Single-blind and Multicenter Study","status":"UNKNOWN","sponsor":"Aier School of Ophthalmology, Central South University","isPivotal":false,"enrollment":150,"indication":"Rhegmatogenous Retinal Detachment, Surgery","completionDate":"2021-12-01"},{"nctId":"NCT01400750","phase":"Phase 4","title":"Prospective Randomized Trial Comparing Oral Ciproxin Plus Inhaled Colistin With Tobramycin for Inhalation for Eradication of P Aeruginosa Infection in Children With Cystic Fibrosis.","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":false,"enrollment":61,"indication":"Cystic Fibrosis","completionDate":"2011-05"},{"nctId":"NCT04342507","phase":"NA","title":"Effects of Probiotic Oral Supplementation on the Treatment of Chalazion in Adults: a Pilot Study on 20 Patients","status":"COMPLETED","sponsor":"University of Molise","isPivotal":false,"enrollment":20,"indication":"Chalazion","completionDate":"2020-02-29"},{"nctId":"NCT05429671","phase":"Phase 3","title":"Drug Elution Profile and Minimum Inhibitory Concentration of Antibiotic-loaded Cement After Primary Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Rothman Institute Orthopaedics","isPivotal":true,"enrollment":50,"indication":"Total Knee Arthoplasty","completionDate":"2023-11-30"},{"nctId":"NCT01155999","phase":"Phase 3","title":"","status":"COMPLETED","sponsor":"Laboratoires Thea","isPivotal":true,"enrollment":286,"indication":"Purulent Bacterial Conjunctivitis","completionDate":"2011-02"},{"nctId":"NCT03739528","phase":"Phase 3","title":"An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for a","status":"COMPLETED","sponsor":"NTC srl","isPivotal":true,"enrollment":808,"indication":"Cataract","completionDate":"2018-12-19"},{"nctId":"NCT03308253","phase":"Phase 4","title":"Pilot Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection in Vascular Surgery Patients","status":"UNKNOWN","sponsor":"McMaster University","isPivotal":false,"enrollment":60,"indication":"Surgical Site Infection","completionDate":"2019-07"},{"nctId":"NCT04850313","phase":"NA","title":"A Prospective, Randomized, Controlled Clinical Study to Evaluate the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers","status":"TERMINATED","sponsor":"University of Arkansas","isPivotal":false,"enrollment":3,"indication":"Bacterial Corneal Ulcer","completionDate":"2022-09-30"},{"nctId":"NCT02528123","phase":"NA","title":"VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia","status":"COMPLETED","sponsor":"London Vision Clinic","isPivotal":false,"enrollment":114,"indication":"Myopia, Refractive Errors","completionDate":"2020-12-07"},{"nctId":"NCT04213313","phase":"N/A","title":"Consecutive, Case Control Study of Association Between Single Nucleotide Polymorphism of SP-D and Susceptibility and Prognosis of Infectious Keratitis","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":145,"indication":"Infectious Keratitis","completionDate":"2019-06-30"},{"nctId":"NCT00781300","phase":"Phase 4","title":"A Randomized Clinical Trial Comparing the Intraocular Pressure Changes With the Use of Loteprednol and Dexamethasone After Pterygium Surgery","status":"COMPLETED","sponsor":"Federal University of São Paulo","isPivotal":false,"enrollment":35,"indication":"Glaucoma, Open-Angle, Ocular Hypertension","completionDate":"2007-02"},{"nctId":"NCT01116089","phase":"Phase 1","title":"PHARMACOKINETIC STUDY OF BRAMITOB® ADMINISTERED FOR INHALATION BY PARI eFLOW® RAPID ELECTRONIC NEBULIZER VS PARI LC® PLUS NEBULIZER COUPLED WITH THE PARI TURBO BOY® N COMPRESSOR IN CYSTIC FIBROSIS PAT","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","isPivotal":false,"enrollment":25,"indication":"Cystic Fibrosis","completionDate":"2011-10"},{"nctId":"NCT00357773","phase":"Phase 3","title":"Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Laboratoires Thea","isPivotal":true,"enrollment":0,"indication":"Conjunctivitis, Bacterial","completionDate":"2005-06"},{"nctId":"NCT01230593","phase":"NA","title":"A 5-year Multicenter Prospective Randomized Trial Comparing Three Conservative Chalazion Treatments","status":"COMPLETED","sponsor":"McMaster University","isPivotal":false,"enrollment":150,"indication":"Chalazion Unspecified Eye, Unspecified Eyelid, Chalazion Left Eye, Unspecified Eyelid","completionDate":"2016-03"},{"nctId":"NCT00885365","phase":"Phase 3","title":"A Multicentre, Multinational, Open-Label, Randomised, Parallel Group Clinical Trial of Tobrineb®/Actitob®/Bramitob® (Tobramycin Solution for Nebulisation, 300mg Twice Daily in 4mL Unit Dose Vials) Com","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","isPivotal":true,"enrollment":324,"indication":"Cystic Fibrosis","completionDate":"2010-05"},{"nctId":"NCT00388505","phase":"Phase 3","title":"A Randomized, Open-label Multicentre Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder Compared to Tobramycin Solution for Inhalation in Cystic Fibrosis Subjects","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":517,"indication":"Cystic Fibrosis","completionDate":"2009-03"},{"nctId":"NCT03673956","phase":"Phase 1","title":"Topical Antibiotics in Chronic Rhinosinusitis","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":false,"enrollment":19,"indication":"Chronic Rhinosinusitis (Diagnosis)","completionDate":"2021-02-01"},{"nctId":"NCT01641822","phase":"Phase 3","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the ","status":"COMPLETED","sponsor":"Gilead Sciences","isPivotal":true,"enrollment":107,"indication":"Cystic Fibrosis","completionDate":"2015-01"},{"nctId":"NCT03715322","phase":"Phase 3","title":"Efficacy and Safety of Inhaled Tobramycin on Bronchiectasis Colonized With Pseudomonas Aeruginosa: A Randomized, Double-blind, Parallel-group Multicenter Trial","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","isPivotal":true,"enrollment":350,"indication":"Bronchiectasis Adult, Pseudomonas Infections","completionDate":"2021-06"},{"nctId":"NCT00006280","phase":"Phase 2","title":"A Phase II Multicenter Randomized Trial of Tobramycin for Inhalation in Young Children With Cystic Fibrosis","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","isPivotal":false,"enrollment":98,"indication":"Cystic Fibrosis","completionDate":"2002-02"},{"nctId":"NCT04872400","phase":"Phase 4","title":"Acute Application Of Intrawound Antibiotic Powder In Open Extremity Fracture Wounds","status":"COMPLETED","sponsor":"University of Colorado, Denver","isPivotal":false,"enrollment":20,"indication":"Fractures, Open, Wounds and Injuries--Infections","completionDate":"2023-09-30"},{"nctId":"NCT04297631","phase":"Phase 4","title":"Prospective Study Investigating Antibiotic Elution From Free Intra-articular Vancomycin and Tobramycin After Cementless Total Knee Arthroplasty","status":"COMPLETED","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":20,"indication":"Antibotics in Cementless Knees","completionDate":"2020-11-01"},{"nctId":"NCT02734459","phase":"Phase 3","title":"A Multi Center, Open Label, Randomized, Two- Treatment, Single Dose, Crossover, Bioequivalence Study To Compare The Pharmacokinetics Of Marketed Product TobraDex® (Tobramycin And Dexamethasone Ophthal","status":"COMPLETED","sponsor":"Semler Research Center Pvt. Ltd.","isPivotal":true,"enrollment":756,"indication":"Bilateral Cataract","completionDate":"2016-03"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$1.2645/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$455","description":"TOBRAMYCIN 0.3% EYE DROP","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2000-05-18T00:00:00.000Z","mah":"BAUSCH AND LOMB","brand_name_local":null,"application_number":"ANDA064052"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-07-13T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"NDA050789"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-07-07T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA211847"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-08-16T00:00:00.000Z","mah":"HARROW EYE","brand_name_local":null,"application_number":"NDA050818"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-12-10T00:00:00.000Z","mah":"ALEMBIC","brand_name_local":null,"application_number":"ANDA217597"},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":"EMEA/H/C/002155"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Tobi Podhaler","application_number":null}],"patentsNormalised":[{"patent_number":"8869794","territory":"US","patent_type":"Formulation","expiry_date":"2028-09-12T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10207066","territory":"US","patent_type":"Formulation","expiry_date":"2030-11-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":3,"withResults":1},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=tobramycin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:29:49.615890+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:29:49.615642+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:29:55.756180+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:29:48.732669+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=tobramycin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:29:56.495729+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:45.712511+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNINGS Patients treated with Tobramycin Injection and other aminoglycosides should be under close clinical observation, because these drugs have an inherent potential for causing ototoxicity and nephrotoxicity. Neurotoxicity, manifested as both auditory and vestibular ototoxicity, can occur. The auditory changes are irreversible, are usually bilateral, and may be partial or total. Eighth-nerve impairment and nephrotoxicity may develop, primarily in patients having pre-existing renal damage and","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:45.712543+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:29:58.018597+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: 70S ribosome inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:57.571914+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989564/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:29:57.222426+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA209346","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:45.712548+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:30:00.392792+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL3989564"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}